blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2498782

EP2498782 - CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  15.11.2019
Database last updated on 20.05.2024
FormerThe patent has been granted
Status updated on  07.12.2018
FormerGrant of patent is intended
Status updated on  18.06.2018
FormerExamination is in progress
Status updated on  14.04.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Pharmatrophix, Inc.
2198 Sterling Avenue
Menlo Park, CA 94025 / US
[N/P]
Former [2012/38]For all designated states
Pharmatrophix Inc.
2198 Sterling Avenue
Menlo Park, California 94025 / US
Inventor(s)01 / MUNIGETI, Rajgopal
2198 Sterling Avenue
Menlo Park, California 94025 / US
02 / LONGO, Frank M.
2198 Sterling Avenue
Menlo Park, California 94025 / US
 [2019/02]
Former [2012/38]01 / MUNIGETI, Rajgopal
2198 Sterling Avenue
Menlo Park California 94025 / US
02 / LONGO, Frank M.
2198 Sterling Avenue
Menlo Park California 94025 / US
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[N/P]
Former [2019/02]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Former [2012/38]Keen, Celia Mary
J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date10830787.712.11.2010
[2019/02]
WO2010US56537
Priority number, dateUS20090260671P12.11.2009         Original published format: US 260671 P
US20100294279P12.01.2010         Original published format: US 294279 P
US20100350797P02.06.2010         Original published format: US 350797 P
[2012/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011060262
Date:19.05.2011
Language:EN
[2011/20]
Type: A1 Application with search report 
No.:EP2498782
Date:19.09.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 19.05.2011 takes the place of the publication of the European patent application.
[2012/38]
Type: B1 Patent specification 
No.:EP2498782
Date:09.01.2019
Language:EN
[2019/02]
Search report(s)International search report - published on:US19.05.2011
(Supplementary) European search report - dispatched on:EP10.02.2014
ClassificationIPC:C07C309/04, C07C309/30, C07D295/15, A61K31/535, C07D295/145
[2018/25]
CPC:
C07D295/15 (EP,US); C07D295/13 (CN); A61K31/535 (EP,US);
A61P17/00 (EP); A61P17/14 (EP); A61P21/00 (EP);
A61P21/02 (EP); A61P25/00 (EP); A61P25/02 (EP);
A61P25/08 (EP); A61P25/14 (EP); A61P25/16 (EP);
A61P25/28 (EP); A61P3/10 (EP); A61P43/00 (EP);
A61P9/00 (EP); A61P9/10 (EP); C07C309/04 (US);
C07C309/30 (US); C07D295/145 (EP,US); C07B2200/13 (CN,US) (-)
Former IPC [2014/11]A61K31/535, C07D295/145
Former IPC [2012/38]A61K31/535
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/38]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:KRISTALLINE FORMEN AUS NEUROTROPHINMIMETISCHEN VERBINDUNGEN UND IHREN SALZEN[2012/38]
English:CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTS[2012/38]
French:FORMES CRISTALLINES DE COMPOSÉS MIMÉTIQUES DE NEUROTROPHINES ET LEURS SELS[2012/38]
Entry into regional phase11.06.2012National basic fee paid 
11.06.2012Search fee paid 
11.06.2012Designation fee(s) paid 
11.06.2012Examination fee paid 
Examination procedure11.06.2012Examination requested  [2012/38]
03.09.2014Amendment by applicant (claims and/or description)
19.04.2017Despatch of a communication from the examining division (Time limit: M06)
30.10.2017Reply to a communication from the examining division
22.02.2018Despatch of a communication from the examining division (Time limit: M02)
04.05.2018Reply to a communication from the examining division
19.06.2018Communication of intention to grant the patent
26.10.2018Fee for grant paid
26.10.2018Fee for publishing/printing paid
26.10.2018Receipt of the translation of the claim(s)
Divisional application(s)EP18207630.7  / EP3470402
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  19.04.2017
Opposition(s)10.10.2019No opposition filed within time limit [2019/51]
Fees paidRenewal fee
30.11.2012Renewal fee patent year 03
18.11.2013Renewal fee patent year 04
10.11.2014Renewal fee patent year 05
30.11.2015Renewal fee patent year 06
28.11.2016Renewal fee patent year 07
27.11.2017Renewal fee patent year 08
27.11.2018Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.11.2010
AL09.01.2019
AT09.01.2019
CY09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
MK09.01.2019
MT09.01.2019
NL09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
[2022/31]
Former [2021/34]HU12.11.2010
AL09.01.2019
AT09.01.2019
CY09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
MT09.01.2019
NL09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2021/32]HU12.11.2010
AL09.01.2019
AT09.01.2019
CY09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
NL09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2021/26]AL09.01.2019
AT09.01.2019
CY09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
NL09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2020/36]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
MC09.01.2019
NL09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2020/17]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
NL09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
TR09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2020/13]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
NL09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SI09.01.2019
SK09.01.2019
SM09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/52]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
NL09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SK09.01.2019
SM09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/49]AL09.01.2019
AT09.01.2019
CZ09.01.2019
DK09.01.2019
EE09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
NL09.01.2019
PL09.01.2019
RO09.01.2019
RS09.01.2019
SE09.01.2019
SK09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/48]AT09.01.2019
DK09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
NL09.01.2019
PL09.01.2019
RS09.01.2019
SE09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/46]AT09.01.2019
FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
NL09.01.2019
PL09.01.2019
RS09.01.2019
SE09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/39]FI09.01.2019
HR09.01.2019
LT09.01.2019
LV09.01.2019
NL09.01.2019
PL09.01.2019
RS09.01.2019
SE09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
IS09.05.2019
PT09.05.2019
Former [2019/38]FI09.01.2019
LT09.01.2019
NL09.01.2019
PL09.01.2019
SE09.01.2019
BG09.04.2019
NO09.04.2019
GR10.04.2019
PT09.05.2019
Former [2019/37]FI09.01.2019
LT09.01.2019
NL09.01.2019
PL09.01.2019
SE09.01.2019
NO09.04.2019
GR10.04.2019
PT09.05.2019
Former [2019/35]FI09.01.2019
LT09.01.2019
NL09.01.2019
PL09.01.2019
SE09.01.2019
NO09.04.2019
PT09.05.2019
Former [2019/34]FI09.01.2019
LT09.01.2019
NL09.01.2019
SE09.01.2019
NO09.04.2019
PT09.05.2019
Former [2019/33]FI09.01.2019
LT09.01.2019
NL09.01.2019
NO09.04.2019
PT09.05.2019
Former [2019/30]NL09.01.2019
Documents cited:Search[Y]EP0386611  (HOFFMANN LA ROCHE [CH]) [Y] 1-13 * 2-Amino-3-methyl-N-(2-morpholinoethyl)-pentanamide; page 20, line 22, paragraph b * * Use in treatment of viral infections :;; claim 27 *;
 [Y]EP0400290  (CIBA GEIGY AG [CH]) [Y] 1-13 * 2-Amino-3-methyl-N-(2-morpholinoethyl)-pentanamide :; page 33; example 24c * * abstract *;
 [Y]WO9616980  (CIBA GEIGY AG [CH], et al) [Y] 1-13 * H-(L)-Ile-N-(2-morpholin-4-yl)-ethylamide :; page 91; compound 5b * * Use as intermediate in synthesis of antiviral compounds : *;
 [IY]WO2006113097  (UNIV NORTH CAROLINA [US], et al) [I] 1-15 * 2-Amino-3-methyl-N-(2-morpholinoethyl)-pentanamide, referred to as "LM11A-31" :;; claims 13, 30; compound 4 * * Use of such compounds in treatment of neurodegenerative disorders :;; claim 1 * * Use as neurotropin mimetic :;; claim 39 * [Y] 1-15;
 [Y]WO2008107365  (MEDIVIR AB [SE], et al) [Y] 1-13 * page 100; example 54 step a * * abstract *;
 [IP]WO2010102212  (UNIV NORTH CAROLINA [US], et al) [IP] 1-15 * 2-Amino-3-methyl-N-(2-morpholinoethyl)-pentanamide for use in treating p75 expression associated disorder, which according to claims 24 and 26 is an neurological disease :;; claims 24, 26, 29-30 * * 2-Amino-3-methyl-N-(2-morpholinoethyl)-pentanamide (all four stereoisomers) :; page 6, paragraph 11 * * 2-Amino-3-methyl-N-(2-morpholinoethyl)-pentanamide as HCl salt :; page 87; examples 19, 20 *;
 [Y]  - GOULD ET AL, "Salt selection for basic drugs", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 33, no. 1-3, doi:10.1016/0378-5173(86)90055-4, ISSN 0378-5173, (1986), pages 201 - 217, (19861101), XP025813036 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/0378-5173(86)90055-4
International search[Y]US2003232815  (HAMILTON GREGORY S [US], et al);
 [Y]US6747735  (CHEN PETER [US], et al);
 [Y]US2004208862  (BRADY-KALNAY SUSANN [US], et al);
 [Y]US2004220138  (GERVAIS FRANCINE [CA], et al);
 [Y]US2006014790  (JOHN VARGHESE [US], et al);
 [Y]US2006052406  (FISHER ABRAHAM [IL], et al);
 [Y]US2006246072  (LONGO FRANK M [US], et al);
 [Y]  - SIMONOVIC ET AL., "Crystal structure of human PEDF, a potent antiangiogenic and neurite growth-promoting factor.", PNAS, (20010925), vol. 98, no. 20, pages 11131 - 11135, XP008157966

DOI:   http://dx.doi.org/10.1073/pnas.211268598
 [Y]  - PATTARAWARAPAN ET AL., "Molecular Basis of Neurotrophin-Receptor Interactions.", JOURNAL OF MEDICINAL CHEMISTRY, (20031204), vol. 46, no. 25, XP008157932

DOI:   http://dx.doi.org/10.1021/jm030221q
 [A]  - JELESAROV ET AL., "Isothermal titration calorimetry and differential scanning calorimetry as complementary tools to investigate the energetics of biomolecular recognition.", J. MOL. RECOGNIT., (1999), vol. 12, pages 3 - 18, XP008157970

DOI:   http://dx.doi.org/10.1002/(SICI)1099-1352(199901/02)
Examination   - AKASH JAIN ET AL, "Estimation of Melting Points of Organic Compounds", INDUSTRIAL & ENGINEERING CHEMISTRY RESEARCH., US, (20041101), vol. 43, no. 23, doi:10.1021/ie049378m, ISSN 0888-5885, pages 7618 - 7621, XP055363537

DOI:   http://dx.doi.org/10.1021/ie049378m
    - GUILLORY J K ED - BRITTAIN H G, GENERATION OF POLYMORPHS, HYDRATES, SOLVATES, AND AMORPHOUS SOLIDS, POLYMORPHISM IN PHARMACEUTICAL SOLIDS; [DRUGS AND THE PHARMACEUTICAL SCIENCES ; 95], MARCEL DEKKER INC, NEW YORK * BASEL, PAGE(S) I - II,183, (19990101), ISBN 978-0-8247-0237-3, XP002350313
by applicantUS2006024072
 WO2006113097
 US2007060526
    - GOULD ET AL., INTERNATIONAL JOURNAL OFPHARMACEUTICS, (1986), vol. 33, no. 1-3, pages 201 - 217
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.